NuCana plc (NCNA)

Trade Setup

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase III clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with metastatic pancreatic cancer. 

Stocks found in this category are low priced stocks priced between .50 and $5, with at least 50k shares of average shares trading per day.   The stocks are pausing a trend either up or down, with a new bar over the prior day open or close.  These are high reward to risk stocks with the potential for very sharp moves.  A stop should be maintained at the low of the prior day.   Target prices for exits can be determined by using the next level of resistance higher or by using Fibonacci resistance levels found using TradersPro.